RIVA-OXYBUTYNIN 5 MG
OXYBUTYNIN CHLORIDE : 5 MG · DIN 02242109 · LABORATOIRE RIVA INC.
Health Canada status: CANCELLED POST MARKET
What is RIVA-OXYBUTYNIN?
RIVA-OXYBUTYNIN 5 MG contains OXYBUTYNIN CHLORIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02242109, held by LABORATOIRE RIVA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is RIVA-OXYBUTYNIN called?
The same molecule, OXYBUTYNIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ditropan | Latin | Australia, South Africa |
| Lenditro | Latin | South Africa |
| Oxytrol | Latin | Australia |
| Sandoz Oxybutynin | Latin | South Africa |
| DITROPAN TABLETTA | Latin | Hungary |
| Syferid | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02242109 |
|---|---|
| Brand name | RIVA-OXYBUTYNIN |
| Generic / active ingredient | OXYBUTYNIN CHLORIDE : 5 MG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD04 OXYBUTYNIN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2013 |
| Original market date | 2000-09-21 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02242109 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2242109 |
| Brand name | RIVA-OXYBUTYNIN |
| Active ingredient / INN | OXYBUTYNIN CHLORIDE : 5 MG |
| ATC code | G04BD04 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | LABORATOIRE RIVA INC. |
Which pack is which?
| Strength on the label | 5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is OXYBUTYNIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by SANIS HEALTH INC, last seen 04 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code G04BD04 OXYBUTYNIN. 5 of 35 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXYBUTYNIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02163543 |
| PMS-OXYBUTYNIN | 2.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02240549 |
| PMS-OXYBUTYNIN | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02240550 |
| PMS-OXYBUTYNIN | 5 MG / 5 ML | SYRUP | PHARMASCIENCE INC | MARKETED | DIN 02223376 |
| TEVA-OXYBUTYNIN | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02230394 |
| ALBERT OXYBUTYNIN | 5 MG | TABLET | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02220067 |
| APO-OXYBUTYNIN | 1 MG | SYRUP | APOTEX INC | DORMANT | DIN 02231089 |
| AVA-OXYBUTYNIN | 5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363917 |
| DITROPAN SYRUP 1MG/ML | 1 MG | SYRUP | JANSSEN INC | CANCELLED POST MARKET | DIN 01924753 |
| DITROPAN TABLETS 5MG | 5 MG | TABLET | JANSSEN INC | CANCELLED POST MARKET | DIN 01924761 |
Who else supplies OXYBUTYNIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXYBUTYNIN appears in 39 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does OXYBUTYNIN cost around the world?
OXYBUTYNIN is listed on 8 national price registers Nexara tracks, across 62 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 40 | 03 Sep 2026 |
| South Africa | single exit price | 4 | 8 | 01 Sep 2026 |
| Australia | ex-manufacturer | 2 | 4 | 08 Sep 2026 |
| United Kingdom | hospital | 4 | 4 | 31 Aug 2026 |
| Romania | max producer price | 1 | 3 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.